Detalhe da pesquisa
1.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother
; 71(4): 865-874, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34462870
2.
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
J Transl Med
; 17(1): 376, 2019 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31730009
3.
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Thorac Cancer
; 12(6): 880-889, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33527756
4.
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
Eur J Cancer
; 142: 18-28, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33212418
5.
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
J Immunother Cancer
; 8(2)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33077515
6.
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
Clin Lung Cancer
; 21(6): 498-508.e2, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32680806
7.
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.
J Immunother Cancer
; 8(2)2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33154150
8.
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.
Cancers (Basel)
; 12(5)2020 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32429380
9.
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.
Oncoimmunology
; 9(1): 1710389, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32002308
10.
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study.
J Cancer Res Clin Oncol
; 145(9): 2365-2373, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31280347
11.
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.
J Immunother Cancer
; 7(1): 57, 2019 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30813970
12.
Unexpected long survival of brain oligometastatic non-small cell lung cancer (NSCLC) treated with multimodal treatment: a single-center experience and review of the literature.
Transl Lung Cancer Res
; 5(6): 712-719, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28149766